Clinical Trial Update: Study Evaluating Intravenous CMD-193 in Subjects With Advanced Malignant Solid Tumors [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating intravenous CMD-193 in patients with advanced malignant solid tumors has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neoplasms

Drugs mentioned

• CMD-193

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Neoplasms | Phase 1 | Status: TERMINATED